Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Medivir AB ( (SE:MVIR) ) just unveiled an announcement.
Medivir AB announced its participation in the DNB Carnegie Nordic Healthcare conference, where CEO Jens Lindberg will discuss a new Right’s Issue to fund a study comparing the efficacy of their drug candidate fostrox combined with lenvatinib against lenvatinib alone in treating second-line liver cancer. This initiative underscores Medivir’s commitment to advancing cancer treatment options and could significantly impact their market positioning and stakeholder interests.
The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.
More about Medivir AB
Medivir AB is a pharmaceutical company focused on developing innovative cancer treatments, particularly in areas with high unmet medical needs. The company is dedicated to creating drug candidates for indications where current therapies are limited or non-existent, with a focus on fostroxacitabine bralpamide (fostrox) for liver cancer. Medivir operates through collaborations and partnerships and is listed on Nasdaq Stockholm’s Small Cap list.
Average Trading Volume: 731,957
Technical Sentiment Signal: Sell
Current Market Cap: SEK49.35M
See more data about MVIR stock on TipRanks’ Stock Analysis page.